Global Alzheimer’s Therapeutic Market Overview:
As per MRFR analysis, the Alzheimer’s Therapeutic Market Size was estimated at 15.42 (USD Billion) in 2022. The Alzheimer’s Therapeutic Market is expected to grow from 16.72 (USD Billion) in 2023 to 34.6 (USD Billion) by 2032. The Alzheimer’s Therapeutic Market CAGR (growth rate) is expected to be around 8.42% during the forecast period (2024 - 2032).
Key Alzheimer’s Therapeutic Market Trends Highlighted
The Alzheimer’s therapeutic market is witnessing a surge in demand due to the rising prevalence of Alzheimer’s disease. Governments and healthcare organizations are actively investing in research and development to identify effective treatments and therapies.
Technological advancements, including the use of artificial intelligence and machine learning, are revolutionizing drug discovery and enabling personalized treatment plans. Partnerships between pharmaceutical companies and research institutions are accelerating the innovation process.
The market is also fueled by growing awareness and advocacy efforts, leading to increased funding and support for Alzheimer’s research. Additionally, the increasing geriatric population and the growing burden of chronic diseases are driving the demand for Alzheimer’s therapeutics.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Alzheimer’s Therapeutic Market Drivers
Rising Prevalence of Alzheimer’s Disease
Alzheimer’s disease is a progressive neurodegenerative disorder that affects memory, thinking, and behavior. It is the most common type of dementia, accounting for 60-80% of cases. The prevalence of Alzheimer’s disease is increasing worldwide, due to the aging population and increasing life expectancy.
According to the Alzheimer’s Association, there are currently over 55 million people living with Alzheimer’s disease worldwide, and this number is expected to reach 135 million by 2050.
The rising prevalence of Alzheimer’s disease is a major driver of the growth of the Alzheimer’s Therapeutic Market.
Growing Demand for Effective Treatments
There is a growing demand for effective treatments for Alzheimer’s disease. Currently, there is no cure for Alzheimer’s disease, but there are a number of treatments that can help to manage the symptoms of the disease.
These treatments include cholinesterase inhibitors, memantine, and antipsychotics. However, these treatments are only partially effective, and they do not stop the progression of the disease. There is a need for new and more effective treatments for Alzheimer’s disease, and this is driving the growth of the Alzheimer’s Therapeutic Market.
Government Support for Alzheimer’s Research
Governments around the world are providing increasing support for Alzheimer’s research. This support is being used to fund clinical trials of new treatments, as well as to develop new diagnostic tools and technologies. Government support for Alzheimer’s research is a major driver of the growth of the Alzheimer’s Therapeutic Market.
Alzheimer’s Therapeutic Market Segment Insights:
Alzheimer’s Therapeutic Market Drug Type Insights
The Alzheimer’s Therapeutic Market is segmented by Drug Type into Cholinesterase Inhibitors, N-methyl-D-aspartate (NMDA) Receptor Antagonists, Monoclonal Antibodies, Beta-secretase Inhibitors, Glutamate Modulators, and Tau Aggregation Inhibitors.
Cholinesterase Inhibitors Cholinesterase inhibitors are the most commonly prescribed drugs for Alzheimer’s disease. The growth of the market is being driven by the increasing prevalence of Alzheimer’s disease and the rising demand for effective treatments.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Alzheimer’s Therapeutic Market Route of Administration Insights
The Alzheimer’s Therapeutic Market is segmented into various routes of administration, including oral, intravenous, subcutaneous, and transdermal. The oral route of administration accounted for the largest share of the market in 2023, owing to its convenience, cost-effectiveness, and ease of administration.
The intravenous route of administration is anticipated to grow at the fastest CAGR during the forecast period, due to the increasing prevalence of severe Alzheimer’s disease cases that require immediate and targeted therapy.
The subcutaneous and transdermal routes of administration are also expected to witness steady growth, as they offer advantages such as sustained drug delivery and reduced side effects. The Alzheimer’s Therapeutic Market segmentation provides valuable insights into the market dynamics and helps stakeholders make informed decisions.
Alzheimer’s Therapeutic Market Patient Population Insights
Alzheimer’s Therapeutic Market segmentation by Patient Population into Early-Stage Alzheimer’s Disease, Moderate-to-Severe Alzheimer’s Disease, and Prodromal Alzheimer’s Disease provides valuable insights into the market dynamics.
Early-Stage Alzheimer’s Disease segment held the largest market share in 2023, accounting for approximately 45% of the Alzheimer’s Therapeutic Market revenue.
This is attributed to the increasing prevalence of early diagnosis and the availability of various treatment options for this stage. The Moderate-to-Severe Alzheimer’s Disease segment is expected to exhibit a significant CAGR during the forecast period, owing to the rising number of patients progressing to advanced stages of the disease.
The Prodromal Alzheimer’s Disease segment is anticipated to witness steady growth, driven by the growing awareness and research efforts aimed at identifying and treating patients in the early stages of cognitive decline.
Alzheimer’s Therapeutic Market End-Use Setting Insights
The End-Use Setting segment of the Alzheimer’s Therapeutic Market is segmented into Hospitals, Clinics, Nursing Homes, and Home Care. Hospitals are expected to hold the largest market share, driven by increasing admissions and preference for advanced treatment facilities.
Clinics are projected to witness significant growth due to the rising number of geriatric patients and the availability of specialized care. Nursing Homes are expected to grow steadily, fueled by the increasing demand for long-term care services. Home Care is anticipated to gain traction as a result of the growing preference for home-based treatments and the availability of advanced home care devices.
Alzheimer’s Therapeutic Market Regional Insights
The Alzheimer’s Therapeutic Market is segmented regionally into North America, Europe, Asia Pacific, South America, and the Middle East and Africa. North America is the largest regional market for Alzheimer’s Therapeutics, accounting for over 40% of the market revenue in 2023.
The high prevalence of Alzheimer’s disease in the region, along with the presence of major pharmaceutical companies, drives the market growth. Europe is the second largest market, followed by Asia Pacific. The Asia Pacific region is expected to witness significant growth in the coming years, due to the rising geriatric population and increasing awareness of Alzheimer’s disease.
South America and the Middle East and Africa are relatively smaller markets, but they are expected to grow at a steady pace in the coming years.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Alzheimer’s Therapeutic Market Key Players and Competitive Insights:
Major players in the Alzheimer’s Therapeutic Market are constantly striving to develop innovative treatments and therapies to address the unmet needs of patients. They are actively involved in research and development, collaborating with academia and other organizations to advance the understanding of Alzheimer’s disease and identify novel therapeutic targets.
Furthermore, leading Alzheimer’s Therapeutic Market players are focusing on strategic partnerships, acquisitions, and mergers to expand their product portfolios and gain a competitive edge in the market. The Alzheimer’s Therapeutic Market is characterized by a high level of competition, with several key players vying for market share.
These companies are investing heavily in research and development to bring new and improved treatments to the market and are also engaging in strategic partnerships and acquisitions to expand their product offerings and geographic reach.
The competitive landscape of the Alzheimer’s Therapeutic Market is expected to remain dynamic, with new entrants and technologies constantly emerging, driving innovation and shaping the future of the market.
Biogen is a leading Alzheimer’s Therapeutic Market player with a strong focus on developing innovative treatments for neurodegenerative diseases. The company has a robust pipeline of investigational therapies targeting different aspects of Alzheimer’s disease, including aducanumab, a monoclonal antibody that targets amyloid beta plaques in the brain.
Biogen is also exploring other potential therapeutic approaches, such as tau-targeting therapies and synaptic function modulators. The company's commitment to research and development, combined with its commercial capabilities, positions it well to maintain a leading position in the Alzheimer’s Therapeutic Market.
Eli Lilly and Company is another major player in the Alzheimer’s Therapeutic Market. The company has a long history of research and development in the field of neurology and is actively involved in the development of new treatments for Alzheimer’s disease.
Eli Lilly's Alzheimer’s disease pipeline includes donanemab, a monoclonal antibody targeting amyloid beta plaques, and solanezumab, a monoclonal antibody targeting soluble amyloid beta oligomers.
The company is also exploring other therapeutic approaches, such as tau-targeting therapies and neuroprotective agents. Eli Lilly's strong research capabilities and commercial infrastructure make it a formidable competitor in the Alzheimer’s Therapeutic Market.
Key Companies in the Alzheimer’s Therapeutic Market Include:
- Novartis AG
- Roche Holding AG
- Shionogi Co., Ltd.
- Biogen Inc.
- AbbVie Inc.
- Eisai Co., Ltd.
- Merck Co., Inc.
- AstraZeneca plc
- Sumitomo Dainippon Pharma Co., Ltd.
- Actelion Pharmaceuticals Ltd.
- Lundbeck A/S
- Janssen Pharmaceuticals, Inc.
- Takeda Pharmaceutical Company Limited
- Eli Lilly and Company
Alzheimer’s Therapeutic Market Developments
The increasing prevalence of Alzheimer’s disease, coupled with the growing geriatric population, is primarily driving market growth. Ongoing research and development efforts, including the exploration of novel treatment modalities such as gene therapy and immunotherapy, are anticipated to further contribute to market expansion.
Strategic collaborations and acquisitions among key players are also shaping the competitive landscape, aiming to strengthen portfolios and enhance market presence.
Alzheimer’s Therapeutic Market Segmentation Insights
- Alzheimer’s Therapeutic Market Drug Type Outlook
- Cholinesterase Inhibitors
- N-methyl-D-aspartate (NMDA) Receptor Antagonists
- Monoclonal Antibodies
- Beta-secretase Inhibitors
- Glutamate Modulators
- Tau Aggregation Inhibitors
- Alzheimer’s Therapeutic Market Route of Administration Outlook
- Oral
- Intravenous
- Subcutaneous
- Transdermal
- Alzheimer’s Therapeutic Market Patient Population Outlook
- Early-Stage Alzheimer’s Disease
- Moderate-to-Severe Alzheimer’s Disease
- Prodromal Alzheimer’s Disease
- Alzheimer’s Therapeutic Market End-Use Setting Outlook
- Hospitals
- Clinics
- Nursing Homes
- Home Care
- Alzheimer’s Therapeutic Market Regional Outlook
- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa
|
Report Attribute/Metric
|
Details
|
|
Market Size 2022
|
15.42(USD Billion)
|
|
Market Size 2023
|
16.72(USD Billion)
|
|
Market Size 2032
|
34.6(USD Billion)
|
|
Compound Annual Growth Rate (CAGR)
|
8.42% (2024 - 2032)
|
|
Report Coverage
|
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
|
|
Base Year
|
2023
|
|
Market Forecast Period
|
2024 - 2032
|
|
Historical Data
|
2019 - 2023
|
|
Market Forecast Units
|
USD Billion
|
|
Key Companies Profiled
|
Novartis AG, Roche Holding AG, Shionogi Co., Ltd., Biogen Inc., AbbVie Inc., Eisai Co., Ltd., Merck Co., Inc., AstraZeneca plc, Sumitomo Dainippon Pharma Co., Ltd., Actelion Pharmaceuticals Ltd., Lundbeck A/S, Janssen Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company
|
|
Segments Covered
|
Drug Type, Route of Administration, Patient Population, End-Use Setting, Regional
|
|
Key Market Opportunities
|
Rising geriatric population, increasing prevalence of Alzheimer’s, technological advancements, unmet medical need, and growing government support.
|
|
Key Market Dynamics
|
Increasing prevalence of Alzheimer’s, growing geriatric population, rising healthcare expenditure, technological advancements, and emerging therapies.
|
|
Countries Covered
|
North America, Europe, APAC, South America, MEA
|
Frequently Asked Questions (FAQ) :
The Alzheimer’s Therapeutic Market size is projected to reach USD 34.6 billion by 2032, exhibiting a CAGR of 8.42% during the forecast period (2024-2032).
North America is expected to account for the largest market share in the Alzheimer’s Therapeutic Market, owing to the high prevalence of Alzheimer’s disease and the presence of major pharmaceutical companies in the region.
The rising prevalence of Alzheimer’s disease, increasing geriatric population, and growing awareness about Alzheimer’s disease are major factors driving the growth of the Alzheimer’s Therapeutic Market.
Alzheimer’s Therapeutics are primarily used for treating the symptoms of Alzheimer’s disease, such as memory loss, confusion, and behavioral changes.
Key competitors in the Alzheimer’s Therapeutic Market include Biogen, Roche, Eisai, Eli Lilly, and Merck.
The Alzheimer’s Therapeutic Market is expected to grow at a CAGR of 8.42% from 2024 to 2032.
Challenges faced by the Alzheimer’s Therapeutic Market include the lack of effective treatments for Alzheimer’s disease, high cost of therapies, and limited reimbursement policies.
Opportunities for growth in the Alzheimer’s Therapeutic Market include the development of new and more effective treatments, increased investment in research and development, and growing awareness about Alzheimer’s disease.
Key trends in the Alzheimer’s Therapeutic Market include the increasing use of combination therapies, the development of personalized medicine approaches, and the growing adoption of digital health technologies.
The Alzheimer’s Therapeutic Market is expected to reach USD 34.6 billion by 2032.
